Skip to main content
Premium Trial:

Request an Annual Quote

Silence Is Not Always Golden

For years, Genome Technology has been poking at the good people of GE Healthcare to let us in on their plans for next-gen sequencing. Now, it seems, the muzzle is off.

In a post on the company's "From Edison's Desk" blog, John Nelson -- best known in this field as one of the minds behind TempliPhi -- writes about his team's work developing a next-gen sequencing platform. After a discussion of how the technology works, Nelson adds, "And yes, if you were wondering whether we are thinking of winning the X-Prize some day using this method, we do hope to. But that's a long way off just now."

Hmm. Do we buy it? GTO wouldn't be surprised if they're closer than they let on.


The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.